Established · publishing since 1966Rising activity
Monoclonal and Polyclonal Antibodies ResearchMultiple Myeloma Research and TreatmentsImmunodeficiency and Autoimmune DisordersChronic Lymphocytic Leukemia ResearchBlood groups and transfusion
Publications
57
Citations
162
Est. group size
—
Recurring co-author estimate
Active years
60
Publishing since 1966
In context
Among 4,953 established Medicine PIs within our index
Citations: 162p25 789 · p75 7,423 · cohort median 2,544
Publications / year (recent): 7.4p25 2 · p75 10.6 · cohort median 4.8
Typically publishes in teams of ~16 · 0% small-team papers (≤3 authors) · across 2 venues
Publication cadence
Publications per year over the last 10 years — averaging 7.4/year recently
Recent publications
- Supplementary Data: Patient Level Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
2025
- Figure S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
2025
- Figure S4 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
2025
- Figure S2 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
2025
- IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
Blood Cancer Discovery · 2023
- NSO-07 Management considerations for dermatologic toxicities associated with talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma
Clinical Lymphoma Myeloma & Leukemia · 2023
- Figure S2 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
2023
- Figure S1 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
2023
- Supplementary Tables S1, S2, S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
2023
- Supplementary Data: Patient Level Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
2023
- Figure S5 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
2023
- Figure S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
2023
- Figure S4 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
2023
- Data from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
2023
- Supplementary Tables S1, S2, S3 from IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies
2023
Publishes in
- Blood Cancer Discovery×1
- bioRxiv (Cold Spring Harbor Laboratory)×1
- Clinical Lymphoma Myeloma & Leukemia×1
- Advances in Methods and Practices in Psychological Science×1
Similar researchers
By research-topic overlap
- Jonathan P. Butchar
Medicine · The Ohio State University
- Susheela Tridandapani
Medicine · The Ohio State University
- Jing Christine Ye
Medicine · University of Michigan
- David F. Keren
Medicine · University of Michigan
- Bhuvaneswari Ramaswamy
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile